Hepatocyte growth factor (HGF) was initially identified in cultured hepatocytes and subsequently reported to induce angiogenic, morphogenic, and antiapoptotic activity in various tissues. These properties suggest a potential influence of HGF on bone healing. We asked if gene transfer of human HGF (hHGF) into an osteotomy gap with a hemagglutinating virus of Japan-envelope (HVJ-E) vector promotes bone healing in rabbits. HVJ-E that contained either hHGF or control plasmid was percutaneously injected into the osteotomy gap of rabbit tibias on Day 14. The osteotomy gap was evaluated by radiography, pQCT, mechanical tests, and histology at Week 8. The expression of hHGF was evaluated by reverse transcriptase-polymerase chain reaction and immunohistochemistry at Week 3. Radiography, pQCT, and histology suggested the hHGF group had faster fracture healing. Mechanical tests demonstrated the hHGF group had greater mechanical strength. The injected tissues at 3 weeks expressed hHGF mRNA by reverse transcriptasepolymerase chain reaction. hHGF-positive immunohistochemical staining was observed in various cells at the osteotomy gap at Week 3. The data suggest delivery of hHGF plasmid into the osteotomy gap promotes fracture repair, and HGF could become a novel agent for fracture treatment.
Introduction
The treatment of fractures has advanced rapidly in recent years. Various implants for treating fractures have been developed [3, 20] . However, complex fractures remain a challenge and often require prolonged fixation. External fixation is the method preferred by many surgeons to stabilize such fractures. However, external fixators are associated with nonunions, pin track infections, and contracture of adjacent joints, some of which relate to the length of the required immobilization.
More rapid bone repair within the fracture gap could minimize the complications that result from prolonged immobilization. Moreover, Einhorn [16] concluded enhancement of the fracture repair process would ensure rapid restoration of function. The ability of injured patients to return earlier to daily life would not only have a substantial economic impact on society, but would also improve the overall physical and mental well-being of the patients. Therefore, a compelling need still exists for a safe and effective way to enhance bone repair.
Many studies report enhancement of fracture healing with hormones or growth factors such as IGF-I [30] , BMP [17, 29, 51] , FGF-2 [4, 10, 42] , VEGF [13] , and PTH [2] . Recent reports suggest another growth factor, hepatocyte growth factor (HGF), functions as a powerful and versatile factors, such as angiogenetic, mitogenic, morphogenic, and antiapoptotic activity. HGF was originally identified from plasma and serum as a molecule that simulated DNA synthesis in rat and human hepatocytes in 1989 [36, 37] . Each author certifies that he or she has no commercial associations (eg, consultancies, stock ownership, equity interest, patent/licensing arrangements, etc) that might pose a conflict of interest in connection with the submitted article. Each author certifies that his or her institution has approved the animal protocol for this investigation and that all investigations were conducted in conformity with ethical principles of research.
Multiple studies subsequently confirmed the role of HGF in enhancing hepatocyte function [21, 25, 27, 28, 39, 45, 47, 49, 50, 52] . Given that many growth factors influence various tissues, the question arises as to whether HGF influences bone healing.
We therefore hypothesized gene transfer of human HGF (hHGF) directly into osteotomy gaps using the hemagglutinating virus of Japan-envelope (HVJ-E) vector would promote tibia fracture healing on radiographs, computer tomography, mechanical tests, and histology in rabbits. Furthermore, we tested the mRNA and protein expression of hHGF to prove the effect of the injected gene.
Materials and Methods
In a preliminary study, we delivered high hHGF concentrations percutaneously and therefore less invasively than an open method to rabbit tibia osteotomy gaps. We used a novel, nonviral vector, the HVJ-E, to deliver hHGF genes to osteotomy gaps. The HVJ-E vector is effective for gene transfer both in vitro and in vivo [26] . Fractures were simulated by an osteotomy with a gap in 50 mature female Japanese white rabbits weighing 2.5 to 3 kg. The rabbits were equally divided into two groups of 25 rabbits each, the hHGF group and the control vector group. Human HGF cDNA (2.2 kb) was inserted between the EcoRI and NotI gaps of the pUC-Sr expression vector plasmid to produce an hHGF expression vector. A pcDNA 3.1(-) plasmid DNA vector (Invitrogen, San Diego, CA) with the same structure, but lacking the hHGF cDNA, was used as a control vector. On Day 7 after injection of HVJ-E, three rabbits in each group were assessed for hHGF mRNA. At 3 and 8 weeks postoperatively, two animals from each group were euthanized for immunohistochemistry. At 8 weeks, the remaining 40 animals were euthanized and equal numbers used for histologic and mechanical testing. The experimental protocol was approved by the Committee on the Ethics of Animal Experiments of Kanazawa University.
HVJ (also known as Sendai virus) envelope vector was prepared as described previously [26] . Briefly, the virus was purified by centrifugation and inactivated by ultraviolet irradiation, which disabled the replication capacity of the virus completely without affecting the cell membrane fusing capability of the envelope. HVJ envelope (5 AU) was mixed with 50 lg of either HGF or pcDNA3.1(-) plasmid DNA and 0.3% Triton-X 100. The suspension was then washed with balanced salt solution (137 mM NaCl, 5.4 mM KCl, 10 mM Tris-HCl; pH 7.6) and centrifuged (10,000 g, 10 minutes) at 4°C, and the pellet was resuspended in a final volume of 100 lL balanced salt solution for subcutaneous injection. The suspension was stored at 4°C until use. HVJ-E vector is commercially available from Ishihara Sangyo Co Ltd (Osaka, Japan).
The rabbits were anesthetized with a subcutaneous injection of ketamine hydrochloride (35 mg/kg body weight; Sankyo Pharmaceutical, Tokyo, Japan), xylazine (5 mg/kg body weight; Bayer, Tokyo, Japan), and an intravenous injection of pentobarbital sodium (40-50 mg/ kg body weight; Abbott Laboratories, North Chicago, IL). A longitudinal skin incision was made on the anteromedial aspect of the right tibia, and the periosteum was carefully stripped of the surrounding soft tissue and fascia. Four half pins 2 mm in diameter (Stryker, Geneva, Switzerland) were inserted into the medial aspect of the tibia, perpendicular to its axis, and a unilateral external fixator of our design was applied. To simulate a fracture of the rabbit tibia [33, 40, 41] , we created a 3-mm gap between the bone fragments with a bone saw.
At postoperative Week 2, after induction of anesthesia with ketamine and xylazine, HVJ-E (100 lL) containing either hHGF or pcDNA 3.1(-) plasmid DNA (n = 25 for each group) was percutaneously injected into the osteotomy gap with a 29-gauge needle (Terumo, Atsugi, Japan) under an image intensifier. The reason we chose postoperative Week 2 was that many new cells existed at the osteotomy gap. Injected gene could be introduced into them.
On Day 7 after percutaneous injection of HVJ-E containing either hHGF or pcDNA 3.1 (-) plasmid DNA (n = 3 for each group), the rabbits were euthanized and the tissue at the osteotomy gap and the surrounding muscle was harvested and prepared for reverse transcriptionpolymerase chain reaction (RT-PCR) to detect hHGF mRNA. The reason why we chose 7 days after delivery was the maximum amount of mRNA from the introduced gene peaked at 5 to 7 days after the injection. Total RNA was isolated using acid guanidinium thiocyanate-phenolchloroform and ethanol precipitation. RT-PCR was performed using an amplification reagent kit (TaqMan EZRT-PCR kit; Applied Biosystems, Alameda, CA) with primers specific for hHGF and rabbit GAPDH. The primer pairs for hHGF (sense primer, 5 0 -ACCCAAGCTGGCTAGCGT-3 0 ; antisense primer, 5 0 -AGTGCTGGATCTATTTTGATTA GG-3 0 ) and rabbit GAPDH (sense primer, 5 0 -GCGCCTG GTCACCAGGGCTGCTT-3 0 ; antisense primer, 5 0 -TGCC GAAGTGGTCGTGGATGACCT-3 0 ) [44] were used to amplify hHGF and rabbit GAPDH. PCR reactions of 40 cycles with annealing temperature of 62°C for 1 minute for hHGF and 26 cycles with annealing temperature 63°C for 1 minute for rabbit GAPDH were performed. The PCR products (hHGF, 260 bp; GAPDH, 465 bp) were separated by electrophoresis in a 3% agarose gel and stained with ethidium bromide. At postoperative Weeks 3 (for the confirmation of the protein expression) and 8 (for the period of the protein expression), two tibias, respectively, from each group were used for immunohistochemistry. Paraffin sections were treated with anti-hHGF monoclonal antibody (R&D Systems Inc, Minneapolis, MN; dilution 1:100), and peroxidase-conjugated goat antimouse immunoglobulin (EnVision; DAKO, Carpinteria, CA) was used as the secondary antibody. To develop the color, a DAB kit (EnVision; DAKO) was used. The sections were counterstained with Mayer's hematoxylin.
To monitor bone formation, we compared the various parameters of healing of osteotomy gaps of the hHGF group with those of the control vector group by radiography at each postoperative time point ( Fig. 1A-B ). The osteotomy gap was evaluated by comparing bone density of the hHGF and control groups (n = 20 for each group) on anteroposterior and medial-lateral radiographs with an aluminum step wedge (10 steps, 1 mm/step) on the same film. Radiographs were obtained weekly under anesthesia for 8 weeks after the operation. We (HT) evaluated the quantity of callus over the entire 3-mm gap between the proximal and distal native bone using Scion Image Beta-3b software for Windows (Scion Corporation, Frederick, MD). Briefly, the bone density of the gap was measured by interpreting the entire image in units of thickness of the aluminum plate by comparing it with the gradient of luminosity obtained from the aluminum wedge. The bone density is reported in units of aluminum thickness (mm Al).
For the quantitative evaluation of the healing process, 10 rabbits in each group were euthanized by an intravenous dose of sodium pentobarbital 8 weeks after surgery after the soft tissues were dissected from the tibia and the external fixator was removed. The tibias were stored in gauze soaked in 0.9% saline solution at -20°C and thawed at room temperature before pQCT and mechanical analysis. A quantitative determination of callus development was performed with pQCT (XCT-Research SA+; Stratec, Pforzheim, Germany). A 3-mm gap bone section was analyzed with three consecutive transverse pQCT scans 0.77 mm thick, 2.5 mm apart, and with a pixel size of 0.1 9 0.1 mm. The XCT Series software package (Rev 6.00B; Stratec, Pforzheim, Germany) was used to calculate the mineral content (mg/mm), mineralized callus area (mm 2 ), and bone mineral density (mg/cm 3 ) at the gap level. To assess progression of remodeling, areas of higher bone density (greater than 690 mg/cm 3 ) within the callus were measured and separated from areas of low mineral density. The mineral content and the area of this high mineral density callus were calculated. The threshold of 690 mg/ cm 3 was selected because it corresponds to the lower level of cortical bone. Furthermore, electronic sections through the long axis of each tibia were created on three-dimensional reconstructed images.
Both tibiae of each rabbit were mechanically tested using an electromechanical testing machine (model MZ-500D; Maruto Machine, Inc, Tokyo, Japan). A three-point bending test was performed at a rate of 2.5 mm per minute with 100 kgf of weight axial load. The central loading point was adjusted toward the osteotomy gap. The lower loading points were separated 30 mm from each other. Failure load values and load displacement curves were obtained for all samples. The stiffness of each unilateral tibia was calculated as the slope of the linear segment on the load displacement curve. Mechanical data ratios of the mechanical data of the fractured unilateral tibia to the intact tibia (percent failure load and percent stiffness) were calculated.
Ten rabbits in each group were euthanized 8 weeks after surgery, and the histology of the osteotomy gap was studied. Heparinized physiological saline was perfused through both femoral arteries followed by perfusion with 4% paraformaldehyde solution in a phosphate buffer (pH 7.4). The tibias were fixed for 24 hours in the same solution. The tibias were then decalcified with 10% EDTA solution and embedded in paraffin. The specimens were sectioned at a 5-lm thickness parallel to the bone axis and stained with hematoxylin and eosin.
Differences in the bone density, mineral contents, mineralized area, bone mineral density, failure load, and stiffness between the control vector group and the HGF group were determined by Student's t test.
Results
The administration of HVJ-E/hHGF or HVJ-E/pcDNA to the rabbits produced no obvious adverse effects such as sudden death or abnormal weight loss during the 8 weeks of the experiment.
In radiographs, bony callus appeared on the lateral side at postoperative Week 2 in the control vector group and bridged the osteotomy gap at postoperative Week 3. After 3 weeks, the size of the bridging callus was reduced and the callus became gradually calcified at the osteotomy gap. At postoperative Week 8, however, corticalization was not sufficient to complete remodeling. The hHGF group demonstrated a similar course as the control vector group until postoperative Week 3. After that time point, the callus at the osteotomy gap became calcified to a greater extent and more rapidly than that of the control vector group. Furthermore, remodeling, especially corticalization and formation of the medullary canal, progressed in the hHGF group. At postoperative Week 8, remodeling in the hHGF group was complete, and the osteotomy gap looked homogeneous when compared with the host bone.
The bone density in the hHGF group was greater compared with the control vector group at postoperative Weeks 4 to 8 (Week 2, p = 0.3675; Week 4, p = 0.0099; Week 6, p = 0.0002; Week 8, p = 0.0093) ( Table 1 ; Fig. 2 ). Mineral content in the hHGF group was greater (p = 0.006) at postoperative Week 8 compared with the control vector group (control vector group, 18.7 ± 4.7 mg/mm; hHGF group, 25.7 ± 5.4 mg/mm) (Fig. 3A) . Mineralized callus area in the hHGF group was also greater (p = 0.015) at postoperative Week 8 compared with the control vector group (control vector group, 19.4 ± 4.9 mm 2 ; hHGF 4.5 (Fig. 3B ). In addition, bone mineral density in the hHGF group was not different (p = 0.059) at postoperative Week 8 compared to the density in the control vector group (control vector group, 933.5 ± 67.3 mg/cm 3 ; hHGF group, 987.7 ± 52.7 mg/ cm 3 ) ( Fig. 3C ). Three-dimensional computed tomographic reconstructed images and axial images of specimens obtained 8 weeks after surgery were created ( Fig. 4A-B ). The osteotomy gaps in the control vector specimen were not bridged completely with a partial defect of the cortical bone. However, no gap was observed in the osteotomy gap of the hHGF group (Fig. 4A ). On the axial view, the osteotomy gaps in the hHGF group had a circular, thick cortical bone. In contrast, the cortex in the control vector group had a partial defect of circular cortical bone (Fig. 4B) . The mean ratio of failure loads of the hHGF group was greater (p = 0.037) than that of the control vector group (89.4% ± 17.5% versus 76.3% ± 9.1%, respectively) (Fig. 5A) . The hHGF-treated tibiae were relatively stiffer (p = 0.001) than those of the control group when both were compared with their contralateral controls (69.7% ± 6.5% versus 57.5% ± 6.3%) ( Fig. 5B) .
At postoperative Week 8 in the hHGF group, the osteotomy gaps were completely remodeled with a firm cortex and a reconstructed medullary canal almost identical to that of normal bone. In contrast, a medullary canal was not observed in the control vector group. In place of a medullary canal, mature cartilage and new trabecular bone were present in the middle of the osteotomy gap, which was not remodeled sufficiently ( Fig. 6 ). In RT-PCR, expression of hHGF mRNA was detected only in the callus of the hHGF group and in the surrounding muscle of neither group (Fig. 7) . Thus, HVJ-E/hHGF was transfected locally into the osteotomy gap sufficiently to express mRNA. By immunohistochemistry, we observed expression of hHGF in immature cells, fibroblasts, osteoblasts, and osteocytes (Fig. 8A) . No immunohistochemical staining was observed in the surrounding muscle of the hHGF group. No hHGF-positive cells were observed in specimens from the control vector group. This indicates the HVJ-E/ hHGF was transfected locally into the osteotomy gap at the level of protein. Human HGF expression was still observed at this time point; however, when expression at 8 weeks was compared with that at 3 weeks, hHGF protein decreased by the end point of treatment (Fig. 8B ). 
Discussion
HGF was originally identified from rat and human hepatocyte. Multiple studies subsequently confirmed the role of HGF in enhancing hepatocyte function. After that, HGF was recognized as a powerful and versatile factor with angiogenesis, mitogen, morphogen, and antiapoptotic activity in various tissues. The question arose as to whether HGF influences bone healing. We therefore hypothesized gene transfer of hHGF directly into osteotomy gaps would promote bone healing in the rabbit. We note several limitations. First, we followed the repair process only 8 weeks. Although this time period was chosen because the control model showed bone union and corticalization on radiographs at postoperative Week 8, our mechanical test data did not reach that of the intact bones. Different results may occur at later stages of healing. However, this study demonstrates bone healing differences resulting from HGF, especially at an early stage. Second, we did not confirm the duration of hHGF gene expression. Because in a clinical setting gene therapy always accompanies the problem of its safety, we should ascertain its safety until at least the end of expression. We gave priority to economic and practical reasons. Third, the gap size was not critical (i.e., nonunion would develop without treatment). Although the osteotomy model is not a fracture the healing process of both models was the same [33, 40, 41] .
Our data suggest percutaneous injection of HVJ-E/ hHGF into tibial osteotomy gaps effectively promotes bone repair. Consequently, the treatment time for fractures could be shortened when the hHGF gene is administered during the early stages of fracture repair. These data indicate the high potential of hHGF gene therapy using the HVJ-E vectors for treatment of bone fractures. Some osteogenetic factors have been used as therapeutic molecules for fracture healing and promote fracture repair. HGF, however, has not been used for this purpose to date. Many papers have been published describing therapeutic uses of HGF for various diseases such as limb ischemia [28, 49, 50] , myocardial ischemia [5] , brain ischemia [47, 52] , hearing impairment [39] , nerve injury [27] , and spinal cord injury [45] . Notably, HGF plasmid delivery for peripheral limb ischemia is now in clinical trials [34] .
HGF along with vitamin D promote growth and differentiation of human mesenchymal cells into osteogenic cells [12] . HGF also enhances osteoblast differentiation in vitro [22] . Further, HGF reportedly contributes to fracture repair by inducing the expression of BMP receptors during the early phase of fracture repair [24] . Our data support previous data suggesting the use of HGF for fracture repair will induce expression of BMPR, which will differentiate mesenchymal cells into osteoblasts and osteoblasts into ossification. Based on these observations, the use of HGF together with other factors such as BMP or vitamin D could enhance fracture healing more rapidly.
Gene delivery to bone has been accomplished by several vectors, including adenovirus, retrovirus, adenoassociated virus, lentivirus, and herpes simplex virus. In this study, we used the HVJ-E vector system as the delivery method for bone osteotomy gaps. HVJ-E is a novel vector system that converts inactivated HVJ into a gene transfer vector by introducing plasmid DNA directly into inactivated HVJ particles after treatment with a mild detergent and centrifugation in the presence of plasmid DNA [26] . Previous studies demonstrated the successful delivery of DNA to cultured cells and animal tissues such as the inner ear [39] , liver, skin, uterus, lung, eye, tumor tissues [26] , and brain [46] . HVJ-E is a nonviral vector that is generally less efficient than other viral delivery vehicles. However, it is inexpensive, safe, nonimmunogenic, and easy to handle [19] .
In principle, gene delivery is performed in two ways, in vivo or ex vivo [8, 9, 14] . In vivo gene delivery is a direct approach, in which the vector is injected directly into the specified target tissue. Ex vivo is an indirect approach, in which the therapeutic gene is delivered outside the body to various cells grown in culture before implantation into the body. In vivo gene delivery involves directly delivering the gene into a specific anatomic gap. The advantages of this method are that it is a simple technique favoring its transfer into a clinical application and that it has the potential for lower costs. The disadvantages are the difficulties in targeting specific cells for transduction and in achieving high transduction efficiency [14] . Ex vivo gene transfer is considered safer because transfected cells are introduced into the body, and safety tests are possible before introduction. However, it is technically more complex and more expensive.
We used gene delivery rather than protein delivery. Gene therapy has potential advantages over protein delivery as a result of (1) long-term expression of the protein from the delivered gene; (2) high local concentration of protein expression; (3) low manufacturing cost; (4) reduced systemic effects; and (5) longer shelf life and easier storage of vectors [31, 32, 38, 48] . Ido et al. [23] reported recombinant hHGF administered intravenously was rapidly decreased in serum with a short half-life of 2.4 minutes. We detected expression of hHGF 6 weeks after the injection of plasmid. Therefore, gene transfer of HGF plasmid is expected to generate much longer expression of HGF than direct administration of HGF protein. Yoshimura et al. [52] also demonstrated gene transfer of HGF plasmid markedly increased cerebral blood flow in the ischemic brain, whereas a single injection of recombinant HGF failed to do so.
Multiple studies relate to gene therapy for bone defects and fractures [6-8, 15, 18, 43] . However, therapeutic gene therapy for bone regeneration with a nonviral vector has never been demonstrated. Egermann et al. [15] reported inflammation resulting from an immune reaction to adenovirus vectors caused severe retardation of bone formation. Similar results occurred with injection of Ad-BMP-2 into muscles of immunocompetent rats, causing poor bone formation and an inflammatory response at the injection gap [1] .
Furthermore, a small number of studies address direct percutaneous injection of a gene to a fracture gap [7, 8, 43] . Gene transfer by direct percutaneous injection leading to endogenous bioactive protein expression offers the potential advantage of simple direct delivery without the requirement for a carrier or surgery and could be used to treat closed fractures in clinical cases. Rundle et al. [43] also performed percutaneous injection of the BMP-4 gene with a retroviral vector into the subperiosteum, which required the deposit of all vector within the periosteum while avoiding the muscle. Therefore, it was technically difficult and not practical. Percutaneous injections of gene to muscle are widely used to promote bone repair resulting from the high efficiency and ease of transfection and longer duration of gene expression [1, 11, 35] . With intramuscular injections, however, the area of gene expression is uncertain, which raises questions about the effect of gene expression at the fracture gap. Furthermore, the immune response differs between intraosseous and intramuscular gaps, because the muscle has a stronger immunologic reaction [6] .
Our preliminary data suggest HGF promotes fracture healing in rabbit tibia and in vivo gene therapy using HVJ-E/hHGF effectively enhances bone formation in fracture healing. Use of these methods could shorten treatment time, resulting in improved physical and mental well-being of patients. In the future, the safety evaluation of this gene therapy technique and the mechanisms whereby HGF promotes bone healing should be assessed further.
